MIMETAS in the global news. Read more about our latest research, developments, collaborations, and product launches.
Sign up for our newsletter to stay up to date.
Leiden, September 14, 2023 – MIMETAS Scientists established a high-throughput human BBB-on-a-chip to study neuroinflammation and transendothelial migration.
Leiden, August 1, 2023 – MIMETAS researchers report the first large-scale phenotypic screen utilizing Organ-on-a-Chip (OoC) technology. This groundbreaking study was published in the Journal of Angiogenesis.
Leiden July 14, 2023 - A placenta on a chip developed at the University of Dundee has the potential to transform research into life-threatening conditions in pregnancy.
Utrecht, 30 June 2023 - The Center for Animal-Free Biomedical Translation (CPBT) is planning to accelerate the transition to animal-free biomedical innovations. This should offer economic and social benefits: improved medicines and fewer animal tests. MIMETAS (Leiden, The Netherlands), the renowned leader in human tissue and disease modeling using organ-on-a-chip technologies, proudly announces its partnership in the CPBT consortium, focusing on ALS, lower back pain, and protein transition & food allergy. This collaboration marks a significant step towards advancing pharmaceutical, chemical, and food component development while minimizing reliance on animal testing.
Leiden June 20, 2023 – MIMETAS, a global leader in human disease modeling announces that it has expanded its ongoing partnership with Astellas, a global pharmaceutical company, to include automation and application support.
Leiden, May 10, 2023 – MIMETAS scientists develop and characterize a pancreatic ductal adenocarcinoma (PDAC) model and applied it to study the role of the endothelium and the stroma in immune cell migration.
Leiden, May 5, 2023 – MIMETAS researchers develop an in vitro model of the placental barrier, which could aid in understanding preeclampsia (PE) and other placental pathologies associated with hypoxia/ischemia.
Leiden, March 28, 2023 – MIMETAS, a global leader in human disease modeling announces that it has entered into a strategic partnership with Astellas Pharma Inc., a global pharmaceutical company.
Leiden, March 22, 2023 – MIMETAS has achieved major milestones in its partnership with Roche, developing models for Inflammatory Bowel Disease (IBD) and Hepatitis B Virus Infections (HBV).
Leiden, March 7, 2023 - MIMETAS announces that it has launched its Adult Stem Cell-derived Colon and Kidney tubular organoids in an assay ready format.
Leiden, February 24, 2023 – MIMETAS scientists shed light on the potential role of gut-on-a-chip models for studying host-microbial interactions in the context of intestinal physiology.
Leiden, February 3, 2023 – MIMETAS scientists established a 3D Pancreatic Ductal Adenocarcinoma (PDAC) model, enabling the study of cancer treatment response in PDAC organoids.
Leiden, November 2, 2022 – MIMETAS is the winner of the Dutch Innovation Award 2022. This award recognizes the company's considerable focus on innovation, contribution to the reduction of animal experimentation, leadership, organization, cooperation with partners, and market position.
LEIDEN, September 8, 2022 – MIMETAS, a global leader in organ-on-chip-based disease models for drug discovery and development, has appointed Dhaval Patel as Chair of its Board of Directors.
Leiden, February, 2022 – TEDxBoerhaavedistrictStudio guides us through a virtual ‘Walk in the Park’ with inspiring TEDx speakers from the Boerhaavedistrict in Leiden, The Netherlands. This month, Jos Joore (MIMETAS’ CEO) explains why the development of pharmaceuticals is a hugely expensive and uncertain process and offers a possible solution for more efficient drug development.
December 10, 2020 – To put new developments in 3D tissue biology in the limelight, MIMETAS organizes 3D-cember every 3rd of December. Videos of the 2020 live-streamed edition are now available on-demand.
January 23, 2020 – The Hubrecht institute and MIMETAS investigated if venom molecules produced by snake venom gland organoids also function as actual venom using the OrganoPlate® platform.
March 5, 2019 – Leading stem cell research group and global leader in organ-on-a-chip technology develop stem cell-derived kidney tubules in microfluidic chips.
April 11, 2018 – Global leader in organ-on-a-chip technology backed by international syndicate for worldwide commercial expansion and new product development.